Search for: "Hospira, Inc." Results 61 - 80 of 287
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
10 Aug 2017, 9:58 pm by Patent Docs
Hospira, Inc. answered a question that had been lingering since the very first case -- can a reference product sponsor use discovery to obtain information from a biosimilar applicant if it does not receive a copy of the aBLA or other information about the manufacturing process as required by the BPCIA? [read post]
26 Jun 2017, 11:27 am by Jay W. Belle Isle
Over concerns of sterility, Hospira Inc., a Pfizer company, has voluntarily recalled three injectable products, as of June 15, 2017. [read post]
13 Jun 2017, 12:00 pm by Sheppard Mullin
Hospira, Inc., that Metallizing Engineering may remain good law under the AIA. [read post]
13 Jun 2017, 12:00 pm by Daniel Taskalis
Hospira, Inc., that Metallizing Engineering may remain good law under the AIA. [read post]
8 Jun 2017, 3:27 am
Hospira, Inc., that Metallizing Engineering may remain good law under the AIA. [read post]
6 Jun 2017, 9:04 pm by Patent Docs
By Andrew Williams -- On May 25, 2017, the FDA's Oncologic Drug Advisory Committee recommended approval of biologics license application ("BLA") 125545 submitted by Hospira Inc., a Pfizer company, for Retacrit, a proposed biosimilar to Amgen Inc.'s Epogen/Procrit (epoetin alfa). [read post]
7 Dec 2016, 1:03 pm by Neha Mehta
Hospira, Inc., the Federal Circuit held that for the on-sale bar to apply, a product must be the subject of a commercial sale or offer for sale, and that a commercial sale is one that bears the general hallmarks of a sale pursuant to Uniform Commercial Code § 2-106. [read post]
3 Dec 2016, 7:52 am by Gregory B. Williams
Hospira, Inc., Civil Action No. 15-839-RGA (D.Del., November 30, 2016), the Court issued its claim constructions for the two phrases in dispute in claims 1 and 8 of U.S. [read post]